Dual-Target Approach Designed to Modulate Both Innate and Adaptive Immunity Advances Into Clinical Evaluation in Patients With SLENANJING, China, Oct. (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results